Guillain-Barrésyndrome and Human Diploid Cell Rabies Vaccine

Knittel, Thomas; Ramadori, Giorgio; Mayet, W.‐J.; Löhr, H.H.; Büschenfelde, K H Meyer zum

doi:10.1016/s0140-6736(89)92734-7

Cited by 33 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Minor reactions do not last longer than 1 month5'6; major reactions last no more than 3 months. [7][8][9] A third strategy is plausible, in which the patient can be observed for 7 days to determine whether further treatment is necessary. However, the Centers for Disease Control and Prevention insist that treatment decisions about rabies must be made immediately.…”

Section: Methodsmentioning

confidence: 99%

A decision-analytic approach to postexposure rabies prophylaxis.

1994

View full text Add to dashboard Cite

The risks and benefits of postexposure rabies prophylaxis were analyzed from clinical and economic perspectives. A decision-analytic model was constructed by using probability and outcome data from the literature and the state health department. Health outcomes were measured in quality-adjusted life years. In the base case (overweight adult male), treatment is optimal when the probability of animal rabidity is greater than 1 in 2000. Sensitivity analysis showed robustness in the treatment decision; however, the incremental cost-effectiveness ratio ($140,000/quality-adjusted life year) is sensitive to the rabidity probability. Treatment is optimal from the patient's perspective; however, it may not be cost-effective when the probability of rabidity is low.

show abstract

Section: Methodsmentioning

confidence: 99%

A decision-analytic approach to postexposure rabies prophylaxis.

1994

View full text Add to dashboard Cite

show abstract

“…Case reports of neurological illness following human diploid cell rabies vaccine describe either a Guillian-Barré-like syndrome (Bøe & Nyland 1980;Bernard et al 1982;Knittel et al 1989), a relapsing mild hemiplegia (Tornatore & Richert 1990), or three patients with symptoms restricted to an arm, possibly the injection site (Gardner & Pattison 1983) (one followed a fetal bovine kidney cell vaccine, now no longer produced) (Courrier et al 1986). The incidence of neurological disease after these rabies vaccines is no more than after other commonly used vaccines.…”

Section: Managementmentioning

confidence: 99%

Rabies Encephalitis and its Prophylaxis

Warrell

2001

Pract Neurol

View full text Add to dashboard Cite

INTRODUCTION It is possible to provide very efficient prophylaxis against rabies encephalitis, which remains universally fatal in practice. The unique pathogenisis of this neurotropic virus is slowly being unravelled, but the relevance of the paradoxical immunological features remain mysterious. The epidemiology of rabies is being clarified because virus strains can now be classified and identified precisely. Recent developments are reviewed here; also a clinician’s view of rabies, its diagnosis, and of the patients said to have recovered from rabies encephalitis. Rabies is a zoonosis of certain mammal species, endemic in all continents. Only a few European countries, some islands and peninsulas and Antarctica, are free of the fear of rabies, although imported infection is a universal risk. Rabies occurs in separate cycles within dogs and wild mammal vector species (see ‘Post-exposure treatment’, page 24), and the virus sometimes spills over to nonvector species such as humans. Strains of virus from

show abstract

Epidemiology

Hughes

1990

Clinical Medicine and the Nervous System

View full text Add to dashboard Cite

Guillain-Barrésyndrome and Human Diploid Cell Rabies Vaccine

Cited by 33 publications

References 5 publications

A decision-analytic approach to postexposure rabies prophylaxis.

A decision-analytic approach to postexposure rabies prophylaxis.

Rabies Encephalitis and its Prophylaxis

Epidemiology

Contact Info

Product

Resources

About